Piper Sandler raised the firm’s price target on Hinge Health (HNGE) to $71 from $70 and keeps an Overweight rating on the shares. The firm notes the company reported strong Q3 results last night, with revenue and adjusted operating income exceeding the high end of guidance. The revenue beat was driven by yield and flowed through to adjusted operating income at a 93.4% incremental margin. Hinge guided Q4 ahead of consensus and raised the 2025 outlook.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HNGE:
- Hinge Health price target raised to $65 from $61 at Canaccord
- Hinge Health price target raised to $65 from $62 at Barclays
- Hinge Health Reports Strong Q3 2025 Financial Results
- Hinge Health: Strong Financial Performance and Growth Potential Amidst Rising Demand for Digital MSK Solutions
- Hinge Health reports Q3 EPS (2c) vs 1c last year